Erratum (DOI:10.1016/S1474-4422(10)70028-4);Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

The Lancet Neurology

Volumn 9, Issue 4, 2010, Pages 438-446

  Clifford, David B ^a   DeLuca, Andrea ^b   Simpson, David M ^c   Arendt, Gabriele ^d   Giovannoni, Gavin ^e   Nath, Avindra ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Parassitarie ed Immunomediate   (Italy)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CIDOFOVIR; CYCLOPHOSPHAMIDE; DEFLAZACORT; DEXAMETHASONE; ETIRACETAM; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; MEFLOQUINE; MEPREDNISONE; METHOTREXATE; MIRTAZAPINE; MITOXANTRONE; NATALIZUMAB; PREDNISONE; STEROID; VALPROIC ACID;

ADULT; AGED; BONE MARROW TRANSPLANTATION; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTRAST ENHANCEMENT; DISEASE EXACERBATION; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOADSORPTION; JC VIRUS; MALE; MORTALITY; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERSONALITY DISORDER; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RELIABILITY; RISK ASSESSMENT; SEIZURE; SHORT SURVEY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 77949279537     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70097-1     Document Type: Erratum

References (30)

1. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
2. Kleinschmidt-DeMasters B.K., and Tyler K.L. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 353 (2005) 369-374
3. Langer-Gould A., Atlas S.W., Bollen A.W., and Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353 (2005) 375-381
4. Van Assche G., Van Ranst M., Sciot R., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 353 (2005) 362-368
5. Lindå H., von Heijne A., Major E.O., et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361 (2009) 1081-1087
6. Wenning W., Haghikia A., Laubenberger J., et al. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab. N Engl J Med 361 (2009) 1075-1080
7. Major E.O. Reemergence of PML in natalizumab-treated patients-new cases, same concerns. N Engl J Med 361 (2009) 1041-1043
8. Berger J.R., and Houff S. Opportunistic infections and other risks with newer multiple sclerosis therapies. Ann Neurol 65 (2009) 367-377
9. Havrdova E., Galetta S., Hutchinson M., et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8 (2009) 254-260
10. US FDA MedWatch: US Department of Health and Human Services. Tysabri (Natalizumab): Update of Healthcare Professional Information. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm199965.htm (accessed Feb 23, 2010).
11. US FDA MedWatch: US Department of Health and Human Services. IFDA Drug Safety Communication: Risk of Progressive Multifocal Leukoencephalopathy (PML) with the use of Tysabri (natalizumab). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm199872.htm (accessed Feb 23, 2010).
12. Ryschkewitsch C.F., Jensen P., Hou J., Fahle G., Fischer S., and Major E.O. Comparison of PCR-southern hybridisation and quantitative real-time PCR for the detection of JCV and BK viral nucleotide sequences in urine and cerebrospinal fluid. J Virol Methods 121 (2004) 217-221
13. Major E.O., Ryschkewitsch C., Fahle G., et al. The laboratory evaluation for JC virus DNA in cerebrospinal fluid and plasma from multiple sclerosis patients participating in the phase III clinical trials of natalizumab. Mult Scler 11 suppl 1 (2005) s181
14. Khatri B.O., Man S., Giovannoni G., et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72 (2009) 402-409
15. Brickelmaier M., Lugovskoy A., Kartikeyan R., et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother 53 (2009) 1840-1849
16. Marzocchetti A., Tompkins T., Clifford D.B., et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology 73 (2009) 1551-1558
17. Tan K., Roda R., Ostrow L., McArthur J., and Nath A. PML-IRIS in patients with HIV infection. Clinical manifestations and treatment with steroids. Neurology 72 (2009) 1458-1464
18. Huang D., Cossoy M., Li M., et al. Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patients. Ann Neurol 62 (2007) 34-39
19. Chen Y., Bord E., Tompkins T., et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361 (2009) 1067-1074
20. Tan C.S., Kinkel R.P., and Koralnik I.J. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361 (2009) 2489-2490
21. Gorelik L., Goelz S., and Sandrock A.W. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361 (2009) 2487-2488
22. De Gascun C.F., Lonergan R.M., and Hall W.W. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 361 (2009) 2488-2489
23. Jilek S., Jaquiéry E., Hirsch H.H., et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 9 (2010) 264-272
24. Khanna N., Wolbers M., Mueller N.J., et al. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. J Virol 83 (2009) 4404-4411
25. Koralnik I.J., Beaumanoir A., Häusler R., et al. A controlled study of early neurologic abnormalities in men with asymptomatic human immunodeficiency virus infection. N Engl J Med 323 (1990) 864-870
26. Koralnik I.J., Du Pasquier R.A., Kuroda M.J., et al. Association of prolonged survival in HLA-A2+ progressive multifocal leukoencephalopathy patients with a CTL response specific for a commonly recognized JC virus epitope. J Immunol 168 (2002) 499-504
27. Knowles W.A., Pipkin P., Andrews N., et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71 (2003) 115-123
28. Kean J.M., Rao S., Wang M., and Garcea R.L. Seroepidemology of human polyomaviruses. PLoS Pathogens 5 (2009) e1000363
29. Major E.O. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 61 (2010) 35-47
30. Carson K.R., Focosi D., Major E.O., et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10 (2009) 816-824